Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4), consist of options to purchase 611,000 shares of Terns common stock.
The stock options come with a 10-year term and an exercise price of $2.56 per share, matching Terns' closing stock price on April 1, 2025. These options will vest over a four-year period, contingent on continued employment through the vesting dates.
Terns Pharmaceuticals (TERN), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti a piccole molecole per l'oncologia e l'obesità, ha annunciato concessioni di incentivi azionari a due nuovi dipendenti. Le concessioni, approvate nell'ambito del Piano di Incentivi per l'Occupazione 2022 e della Regola di Quotazione Nasdaq 5635(c)(4), consistono in opzioni per acquistare 611.000 azioni di azioni ordinarie di Terns.
Le opzioni sulle azioni hanno un termine di 10 anni e un prezzo di esercizio di 2,56 dollari per azione, corrispondente al prezzo di chiusura delle azioni di Terns del 1 aprile 2025. Queste opzioni matureranno nel corso di un periodo di quattro anni, a condizione di un'occupazione continuativa fino alle date di maturazione.
Terns Pharmaceuticals (TERN), una empresa biofarmacéutica en etapa clínica centrada en desarrollar tratamientos de pequeñas moléculas para la oncología y la obesidad, ha anunciado concesiones de incentivos de capital a dos nuevos empleados. Las concesiones, aprobadas bajo el Plan de Concesiones de Incentivos Laborales 2022 y la Regla de Cotización de Nasdaq 5635(c)(4), consisten en opciones para comprar 611,000 acciones de acciones ordinarias de Terns.
Las opciones sobre acciones tienen un plazo de 10 años y un precio de ejercicio de 2.56 dólares por acción, que coincide con el precio de cierre de las acciones de Terns del 1 de abril de 2025. Estas opciones se consolidarán durante un período de cuatro años, condicionadas a la continuación del empleo hasta las fechas de consolidación.
Terns Pharmaceuticals (TERN), 임상 단계의 생물 제약 회사로서 종양학 및 비만 치료를 위한 소분자 치료제를 개발하는 데 중점을 두고, 두 명의 새로운 직원에게 주식 유인 보상을 발표했습니다. 이 보상은 2022 고용 유인 보상 계획 및 나스닥 상장 규칙 5635(c)(4)에 따라 승인되었으며, 611,000주의 Terns 보통주를 구매할 수 있는 옵션으로 구성됩니다.
주식 옵션은 10년 기간과 주당 2.56달러의 행사 가격을 가지며, 이는 2025년 4월 1일 Terns의 종가와 일치합니다. 이 옵션은 4년 동안의 기간에 걸쳐 발생하며, 발생 날짜까지의 지속적인 고용에 따라 달라집니다.
Terns Pharmaceuticals (TERN), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements à petites molécules pour l'oncologie et l'obésité, a annoncé des concessions d'incitation en capital à deux nouveaux employés. Les concessions, approuvées dans le cadre du Plan de Concessions d'Incentive à l'Emploi 2022 et de la Règle de Cotation Nasdaq 5635(c)(4), consistent en des options pour acheter 611 000 actions des actions ordinaires de Terns.
Les options d'actions ont une durée de 10 ans et un prix d'exercice de 2,56 $ par action, correspondant au prix de clôture des actions de Terns du 1er avril 2025. Ces options seront acquises sur une période de quatre ans, sous réserve d'un emploi continu jusqu'aux dates d'acquisition.
Terns Pharmaceuticals (TERN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von kleinen Molekültherapien für Onkologie und Fettleibigkeit konzentriert, hat Aktienanreize für zwei neue Mitarbeiter angekündigt. Die Anreize, die im Rahmen des 2022 Employment Inducement Award Plans und der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, bestehen aus Optionen zum Kauf von 611.000 Aktien der Stammaktien von Terns.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von 2,56 $ pro Aktie, was dem Schlusskurs von Terns am 1. April 2025 entspricht. Diese Optionen werden über einen Zeitraum von vier Jahren ausgegeben, abhängig von der fortgesetzten Beschäftigung bis zu den Ausgabedaten.
- None.
- None.
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted options to purchase 611,000 shares of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
What is the exercise price for TERN's new employee stock options granted on April 1, 2025?
How many shares of TERN stock were granted in the April 2025 employee inducement awards?
What is the vesting period for TERN's April 2025 employee stock options?
Under which regulatory rule were TERN's April 2025 employee stock options granted?
